The legal question presented in a Pfizer motion for partial summary judgment was whether a drugmaker, which "negligently or intentionally perpetrates a fraud upon the medical community" by the off-label marketing of its name-brand drug, can be held responsible for money paid to other drug companies that make the generic equivalent of the name-brand drug, wrote Philadelphia Common Pleas Judge Mark Bernstein.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments